Diclofenac Sodium (Diclofenac Sodium) Patent Expiration, LOE Window & CMS Spending

Diclofenac Sodium (Diclofenac Sodium) by Novartis: Off-Patent Genericized (AB Competition), 39 AB generics, $434.5M 2024 CMS Part D & Medicaid spend, and $1,308 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN020809 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors39
2024 CMS Total Public Spend$434.5M
2024 Medicare Part D Spend$341.8M
2024 Medicaid Spend$92.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,308 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.